ESR1 and neoplasm: Mutation carriers had a trend toward larger tumor sizes and lower ER/PR positivity rates than non-carriers (tumor sizes > 2 cm: 51.43% vs. 45.63%; ER positivity rates: 51.43% vs. 60.81%; PR positivity rates: 48.57% vs. 55.16%).